Immune-stromal-lymphatic communication shapes the context-dependent relationship between Hashimoto thyroiditis and papillary thyroid carcinoma
Year: 2026
Type: article
Abstract: Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC) frequently coexist, yet their clinical relationship remains paradoxical. Surgical and epidemiological series establish heterogeneous clinical associations: PTC is detected more often in some HT cohorts, whereas coexistent HT is associated with less aggressive disease in many outcome studies. Tissue studies separately establish organized autoimmune inflammation in HT and heterogeneous immune, stromal, endothelial, and lymphatic programs in PTC. What is not established is that these compartments form a single causal mechanism at the HT-PTC interface. The principal contribution of this review is therefore a hypothesis-generating, spatially explicit framework asking whether autoimmune tissue architecture that may predate tumor detection modifies subsequent tumor evolution. We distinguish distant autoimmune follicles from tumor-associated tertiary lymphoid structures (TLSs), and we separate direct HT-PTC observations from HT-only evidence, PTC evidence that is not HT-specific, and mechanistic extrapolation. The proposed framework integrates CCL21-CCR7 and CXCL13-CXCR5 signaling, ACKR1-positive endothelial entry sites, fibroblast states, TLS phenotype and location, and VEGF-C/VEGF-D-VEGFR3-associated lymphatic remodeling. These processes may have different relevance to tumor initiation and to progression after PTC is established. Depending on region, tumor genotype, immune function, stromal state, and tumor-lymphatic proximity, an inflamed gland may support epithelial injury, productive antitumor immunity, an inflamed but ineffective immune state, or lymphatic dissemination. These spatial features remain mechanistic and exploratory prognostic candidates; they are not validated diagnostic, predictive, or treatment-directing biomarkers. Region-matched human studies, functional perturbation, independent retrospective validation, and prospective clinical-utility testing are required.
Source: Frontiers in Immunology
Authors: Yulan Cai, Feng Zeng, Chuyu Liu
Institution: Zunyi Medical University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Awards: G2815179611, G9001344444
OpenAlex ID: W7225914507
